Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
rna interference
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
alnylam pharmaceutials
alnylam pharmaceuticals
aminolevulinic acid
arrowhead pharmaceuticals
biotech
boehringer ingelheim
deals
dicerna pharmaceuticals
drugs
eli lilly
fda
givosiran
hepatitis b
indiana blog main
indiana top stories
johnson & johnson
national top stories
neurodegenerative diseases
onpattro
patisiran
paul matteis
primary hyperoxaluria
san francisco blog main
san francisco top stories
stifel financial
wisconsin blog main
wisconsin top stories
What
ago
2
×
interference
2
×
rna
2
×
rnai
abandoning
alnylam
approval
baggage
companies
cuts
deal
development
dicerna
drug
fda
free
gets
indicated
long
medicine
medicines
nod
pharma
pharmaceuticals
quick
second
seek
signs
small
speedy
wasn’t
weeks
won’t
Language
Current search:
rna
×
ago
×
interference
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug